ZA200400143B - Improved chelator conjugates. - Google Patents
Improved chelator conjugates.Info
- Publication number
- ZA200400143B ZA200400143B ZA200400143A ZA200400143A ZA200400143B ZA 200400143 B ZA200400143 B ZA 200400143B ZA 200400143 A ZA200400143 A ZA 200400143A ZA 200400143 A ZA200400143 A ZA 200400143A ZA 200400143 B ZA200400143 B ZA 200400143B
- Authority
- ZA
- South Africa
- Prior art keywords
- chelator conjugates
- improved
- improved chelator
- radiometal
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0116815.2A GB0116815D0 (en) | 2001-07-10 | 2001-07-10 | Improved chelator conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200400143B true ZA200400143B (en) | 2004-12-29 |
Family
ID=9918227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200400143A ZA200400143B (en) | 2001-07-10 | 2004-01-08 | Improved chelator conjugates. |
Country Status (21)
Country | Link |
---|---|
US (2) | US7597875B2 (no) |
EP (1) | EP1404377B1 (no) |
JP (1) | JP5015409B2 (no) |
KR (1) | KR100892009B1 (no) |
CN (4) | CN101537190A (no) |
AT (1) | ATE304866T1 (no) |
AU (1) | AU2002317317B2 (no) |
BR (1) | BR0210965A (no) |
CA (1) | CA2450690C (no) |
DE (1) | DE60206272T2 (no) |
DK (1) | DK1404377T3 (no) |
ES (1) | ES2250671T3 (no) |
GB (1) | GB0116815D0 (no) |
HK (1) | HK1064585A1 (no) |
HU (1) | HU228850B1 (no) |
IL (1) | IL159388A0 (no) |
MX (1) | MXPA04000210A (no) |
NO (1) | NO334093B1 (no) |
RU (1) | RU2298012C2 (no) |
WO (1) | WO2003006070A2 (no) |
ZA (1) | ZA200400143B (no) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2433657A1 (en) | 2001-01-05 | 2002-07-11 | Duke University | Contrast enhancement agent for magnetic resonance imaging |
IL159310A0 (en) * | 2001-07-10 | 2004-06-01 | Amersham Health As | Peptide-based compounds |
NO20030115D0 (no) * | 2003-01-09 | 2003-01-09 | Amersham Health As | Kontrastmiddel |
GB0416062D0 (en) * | 2004-07-19 | 2004-08-18 | Amersham Plc | Improved N4 chelator conjugates |
EP1699495A2 (en) | 2003-11-06 | 2006-09-13 | Amersham Health AS | Conjugates of angiotensin ii and an imaging moiety |
EP1699494A2 (en) | 2003-11-24 | 2006-09-13 | GE Healthcare AS | Contrast agent imaging angiotensin ii receptors |
EP1729823B1 (en) * | 2004-03-04 | 2009-11-04 | GE Healthcare AS | Conjugates of angiotensin peptidic analogues and chelating agents for diagnosis and therapy |
ATE494913T1 (de) | 2004-11-22 | 2011-01-15 | Ge Healthcare As | Kontrastmittel für eine extrazelluläre matrix |
US20080226555A1 (en) * | 2005-06-08 | 2008-09-18 | Bengt Langstrom | Method for the Use of [11C] Carbon Monoxide in Labeling Synthesis of 11C-Labelled Esters and Acids by Sensitized Photo-Induced Free Radical |
GB0515974D0 (en) * | 2005-08-03 | 2005-09-07 | Ge Healthcare Ltd | Compounds and imaging methods |
EP1989179B1 (en) | 2006-02-15 | 2011-01-26 | Ge Healthcare As | Contrast agents |
US7943117B2 (en) * | 2006-06-08 | 2011-05-17 | Atomic Energy Council—Institute of Nuclear Research | Method for testing radiochemical purity of Tc-99m-TRODAT-1 |
CN102321154A (zh) * | 2006-12-11 | 2012-01-18 | 通用电气医疗集团股份有限公司 | 基于放射性标记的肽的化合物及其用途 |
AU2009322081C1 (en) | 2008-12-02 | 2016-09-01 | Clarity Pharmaceuticals Ltd | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals |
GB0922014D0 (en) | 2009-12-17 | 2010-02-03 | Ge Healthcare Ltd | Novel integrin binders |
CN103108659A (zh) * | 2010-07-27 | 2013-05-15 | 通用电气健康护理有限公司 | 放射性药物组合物 |
GB201103696D0 (en) * | 2011-03-04 | 2011-04-20 | Ge Healthcare Ltd | Technetium labelled peptides |
GB201110767D0 (en) | 2011-06-24 | 2011-08-10 | Ge Healthcare Ltd | Infection imaging |
US20130195756A1 (en) | 2012-01-31 | 2013-08-01 | General Electric Company | 99mTc IMAGING AGENTS AND METHODS OF USE |
WO2014126902A1 (en) * | 2013-02-15 | 2014-08-21 | Thomas Jefferson University | Kit for tumor imaging |
GB201314936D0 (en) | 2013-08-21 | 2013-10-02 | Ge Healthcare Ltd | Radiolabelling method |
GB201322456D0 (en) | 2013-12-18 | 2014-02-05 | Ge Healthcare Ltd | Radiotracer compositions and methods |
WO2015140212A1 (en) | 2014-03-19 | 2015-09-24 | Universität Zürich | Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy |
JP7495126B2 (ja) * | 2018-05-08 | 2024-06-04 | ユニヴァーシティー オブ マイアミ | 組織への治療用核酸の送達のための材料および方法 |
WO2019222454A1 (en) | 2018-05-16 | 2019-11-21 | Emory University | Styrylbenzothiazole derivatives and uses in imaging |
CN111548275A (zh) * | 2020-05-27 | 2020-08-18 | 龙曦宁(上海)医药科技有限公司 | 一种2-(氨基甲基)-n1,n1-二甲基丙烷-1,3-二胺三盐酸盐的合成方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1588978A (en) * | 1977-07-19 | 1981-05-07 | Ici Ltd | Coating processes |
DE3930674A1 (de) * | 1989-09-11 | 1991-03-21 | Diagnostikforschung Inst | Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie |
US5808091A (en) * | 1991-10-29 | 1998-09-15 | Bracco International B.V. | Rhenium and technetium complexes containing a hypoxia localizing moiety |
JP3083157B2 (ja) * | 1993-08-04 | 2000-09-04 | アマーシャム・インターナショナル・ピーエルシー | 酸素欠乏性組織に局在する放射性金属錯体 |
DE69501981T2 (de) * | 1994-01-12 | 1998-12-10 | Bracco International B.V., Amsterdam | Liganden und deren metallkomplexe |
EP0738158B1 (en) * | 1994-01-12 | 2002-04-03 | Amersham plc | Biological targeting agents |
IL139385A (en) | 1998-05-15 | 2005-09-25 | Amersham Plc | Labelled glutamine and lysine analogues, metal complexes thereof, and uses thereof for diagnosis |
US6783711B2 (en) * | 2000-05-23 | 2004-08-31 | Ge Osmonics, Inc. | Process for preparing a sulfonamide polymer matrix |
US6988794B2 (en) * | 2001-03-08 | 2006-01-24 | Matsushita Electric Industrial Co., Ltd. | Inkjet recording ink, method for producing said ink, and ink cartridge and recording device having said ink |
-
2001
- 2001-07-10 GB GBGB0116815.2A patent/GB0116815D0/en not_active Ceased
-
2002
- 2002-07-08 CN CNA200910127855XA patent/CN101537190A/zh active Pending
- 2002-07-08 CN CNA2008102133680A patent/CN101538313A/zh active Pending
- 2002-07-10 KR KR1020047000303A patent/KR100892009B1/ko not_active IP Right Cessation
- 2002-07-10 US US10/483,455 patent/US7597875B2/en not_active Expired - Lifetime
- 2002-07-10 RU RU2003137592/04A patent/RU2298012C2/ru not_active IP Right Cessation
- 2002-07-10 DK DK02745600T patent/DK1404377T3/da active
- 2002-07-10 IL IL15938802A patent/IL159388A0/xx unknown
- 2002-07-10 WO PCT/GB2002/003168 patent/WO2003006070A2/en active IP Right Grant
- 2002-07-10 CN CNB028140087A patent/CN100509061C/zh not_active Expired - Fee Related
- 2002-07-10 DE DE60206272T patent/DE60206272T2/de not_active Expired - Lifetime
- 2002-07-10 AU AU2002317317A patent/AU2002317317B2/en not_active Ceased
- 2002-07-10 HU HU0401265A patent/HU228850B1/hu not_active IP Right Cessation
- 2002-07-10 AT AT02745600T patent/ATE304866T1/de active
- 2002-07-10 BR BR0210965-4A patent/BR0210965A/pt active Pending
- 2002-07-10 MX MXPA04000210A patent/MXPA04000210A/es active IP Right Grant
- 2002-07-10 EP EP02745600A patent/EP1404377B1/en not_active Expired - Lifetime
- 2002-07-10 CA CA002450690A patent/CA2450690C/en not_active Expired - Lifetime
- 2002-07-10 JP JP2003511875A patent/JP5015409B2/ja not_active Expired - Lifetime
- 2002-07-10 CN CN2009102035216A patent/CN101607913B/zh not_active Expired - Fee Related
- 2002-07-10 ES ES02745600T patent/ES2250671T3/es not_active Expired - Lifetime
-
2003
- 2003-12-16 NO NO20035597A patent/NO334093B1/no not_active IP Right Cessation
-
2004
- 2004-01-08 ZA ZA200400143A patent/ZA200400143B/xx unknown
- 2004-09-22 HK HK04107295A patent/HK1064585A1/xx not_active IP Right Cessation
-
2009
- 2009-10-01 US US12/571,508 patent/US8852550B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200400143B (en) | Improved chelator conjugates. | |
MXPA05009682A (es) | Metodos de radiofluorinacion de vectores biologicamente activos. | |
PL1791571T3 (pl) | Radiofluorowane peptydy | |
YU27403A (sh) | Postupak za pripremanje preparata u obliku praha | |
MXPA03006093A (es) | Derivados de n(fenilsulfonil)glicina y su uso terapeutico. | |
HK1068626A1 (en) | Chemical compounds | |
TW200716605A (en) | 2,6-quinolinyl derivatives, processes for preparing them and their uses | |
TWI268278B (en) | 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses | |
WO2003104425A3 (en) | NEW STABLE ANTI-CD22 ANTIBODIES | |
PL1831239T3 (pl) | Sposób wytwarzania gamma-laktonu kwasu 17-hydroksy-6 beta, 7 beta,15 beta, 16 beta-bismetyleno-17 alpha-pregn-4-en-3-ono-21-karboksylowego i związki pośrednie kluczowe dla tego sposobu | |
DE60210598D1 (de) | 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA | |
GB0105224D0 (en) | Improved peptide-chelate conjugates | |
TW200732345A (en) | Niobium compound | |
DE60322562D1 (de) | Konjugate von tc komplexen und zielgerichtete einheiten und ihre verwendung in nmr-diagnostik | |
PL352104A1 (en) | Oral composition containing perlite | |
DE60213084D1 (de) | 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA | |
ATE242763T1 (de) | Methoximinophenylessigsäureamide | |
MXPA05008108A (es) | Exo-(2r)(+))-2-amino-7-azabiciclo[2.2.1]heptan-7-carboxilato de terc-butilo, compuestos intermedios y procedimiento para prepararlos y aislarlos. | |
NO20021429D0 (no) | 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner | |
ITMI20030827A1 (it) | Composizione farmaceutica contenente l'associazione levodopa/carbidopa. | |
TW200407314A (en) | Preparation of 4, 6-dichloro-5-fluoropyrimidine | |
UA86379C2 (ru) | Азотосодержащие гетероарильные соединения и их применение при повышении эндогенного эритропоэтина | |
BG103595A (en) | Metoprolol compound and methods for its preparation | |
TW200519206A (en) | Methods for producing novel medaka and novel medaka | |
ITVR20020030A1 (it) | Miscela per polvere di saldatura, nonché procedimento per l'impiego di detta miscela. |